EO7 Stock Overview
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Endo International plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.002 |
52 Week High | US$0.15 |
52 Week Low | US$0.0002 |
Beta | 0.86 |
1 Month Change | -90.00% |
3 Month Change | -81.82% |
1 Year Change | -98.18% |
3 Year Change | -99.97% |
5 Year Change | -99.97% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
EO7 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -80.0% | 2.1% | 1.6% |
1Y | -98.2% | -26.3% | 6.4% |
Return vs Industry: EO7 underperformed the German Pharmaceuticals industry which returned -26.3% over the past year.
Return vs Market: EO7 underperformed the German Market which returned 6.4% over the past year.
Price Volatility
EO7 volatility | |
---|---|
EO7 Average Weekly Movement | 215.8% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EO7's share price has been volatile over the past 3 months.
Volatility Over Time: EO7's weekly volatility has increased from 129% to 216% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1920 | 2,931 | Blaise Coleman | https://www.endo.com |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company offers branded pharmaceuticals, including XIAFLEX to treat adult patients with Dupuytren’s contracture and Peyronie’s disease; SUPPRELIN LA to treat central precocious puberty in children; AVEED to treat hypogonadism; NASCOBAL nasal spray to treat vitamin B12 deficiency; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET for pain management; TESTOPEL, an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX to treat erectile dysfunction, as well as opioid products to treat pain associated with post-herpetic neuralgia.
Endo International plc Fundamentals Summary
EO7 fundamental statistics | |
---|---|
Market cap | €108.59k |
Earnings (TTM) | -€2.26b |
Revenue (TTM) | €1.86b |
0.0x
P/S Ratio0.0x
P/E RatioIs EO7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EO7 income statement (TTM) | |
---|---|
Revenue | US$2.01b |
Cost of Revenue | US$941.90m |
Gross Profit | US$1.07b |
Other Expenses | US$3.52b |
Earnings | -US$2.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -10.41 |
Gross Margin | 53.17% |
Net Profit Margin | -121.69% |
Debt/Equity Ratio | -123.5% |
How did EO7 perform over the long term?
See historical performance and comparison